Background RA is the most common chronic inflammatory arthropathy. About 30% of patients are treated with BT. The optimisation of TB doses in patients in clinical remission of the disease is a strategy used in clinical practice.
Primary endpoint was evaluate the clinical behaviour of RA in patients of the Rheumatology Unit of Valme University Hospital, who receive BT at optimised doses, according to the BT dose optimisation protocol elaborated in our unit.
Materials and methods Observational, descriptive, longitudinal and retrospective study in a cohort of 32 patients diagnosed with RA, who are treated at optimised doses of TB (2008 −2014).
A description of the baseline characteristics was made.
The clinical evolution was measured by the DAS 28 at different times: prior to the initial reduction and subsequent reductions, at the end of the reduction and at the data collection visit.
Result 62.5% are women, mean age at diagnosis of 42.6 years. The duration of RA at the start of BT was 98.63 months and the biological treatment time at the beginning of the optimisation was 160.66 months.
The 75% of the sample was FR positive and 56.7% ACPA positive. The 59.4% were with etanercept.
The mean DAS28 before the reduction of BT was 2.47.
At the time of analysis 21 continued with optimised doses with DAS 28: 2.67 and 11 had discontinued the dose reduction régimen, 80% by increase of the activity
Conclusions All the patients in our study were in clinical remission at the beginning of TB optimisation.
The optimised TB can maintain a high percentage of patients in clinical remission. One-third of our patients are maintained in optimised doses for a long period.
The main reason to finalise the optimisation regimen was an increase in the activity of the disease.